Stock Markets April 22, 2026 12:00 PM

Tilray Leads Broad Cannabis Rally as Administration Poised to Reclassify Marijuana

Reports that marijuana may be moved to Schedule III send growers and a cannabis ETF sharply higher

By Maya Rios TLRY CGC ACB CRON MSOS
Tilray Leads Broad Cannabis Rally as Administration Poised to Reclassify Marijuana
TLRY CGC ACB CRON MSOS

Shares of several major cannabis companies jumped after reports surfaced that the administration plans to reclassify marijuana as a Schedule III drug, a move that would ease research barriers but would not legalize the substance or alter existing sentences for possession immediately. The news lifted individual growers and a U.S. cannabis ETF.

Key Points

  • Tilray surged 14% after reports the administration plans to reclassify marijuana to Schedule III.
  • Other major cannabis names and a U.S. cannabis ETF posted double-digit gains, including a 25% rise for Canopy Growth.
  • The Schedule III reclassification would ease DEA research barriers but would not legalize marijuana or change existing possession sentences immediately.

Market reaction

Shares of Tilray Brands (NASDAQ:TLRY) rallied strongly, climbing 14% on Wednesday after reports that the administration intends to reclassify marijuana. The broader cannabis sector also experienced notable gains, with Canopy Growth (NASDAQ:CGC) up 25%, Aurora Cannabis (NASDAQ:ACB) rising 13%, and Cronos Group (NASDAQ:CRON) increasing 12%. The AdvisorShares Pure US Cannabis ETF (ARCA:MSOS) gained about 10% on the same news.


Reported policy change

According to Axios, the administration is preparing to move marijuana to Schedule III, following an executive order from the president last year that began the multi-year reclassification process. Under the anticipated change, marijuana would be grouped with substances such as ketamine and anabolic steroids - drugs recognized as having accepted medical uses but that retain some potential for abuse.


Implications highlighted in reports

The shift to Schedule III would lower Drug Enforcement Administration barriers related to research, making it easier to study medical applications of marijuana. That regulatory easing is the specific change described in the reports; the move would not immediately legalize marijuana at the federal level, nor would it alter the sentences of people currently incarcerated for possession.


Significance for the cannabis industry

Industry participants and investors are interpreting the possible reclassification as a meaningful development because federal regulatory constraints have been a persistent challenge even as numerous states have moved to legalize marijuana in various forms. The reported Schedule III designation would represent a different federal stance toward medical research and could affect how companies, researchers, and investors approach the sector.


Related investment note

A promotional analysis referenced a question about whether to invest $2,000 in WEED. It stated that ProPicks AI evaluates WEED alongside thousands of companies monthly using more than 100 financial metrics, assessing fundamentals, momentum, and valuation. The promotional copy noted that the AI strategy has previously identified winners such as Super Micro Computer (+185%) and AppLovin (+157%), and suggested that readers can examine whether WEED appears in current ProPicks AI strategies or if other opportunities exist in the same space.

Risks

  • Reclassification would not immediately legalize marijuana - federal legalization remains unchanged, which affects markets and operations in regulated sectors.
  • The change would not impact sentences for those incarcerated for possession, leaving criminal justice outcomes unaffected in the short term.
  • The reports describe a planned policy change; if implementation details differ from the reports, market reactions could reverse or be muted.

More from Stock Markets

ISS Urges Shareholders to Back Independent Chair at ConocoPhillips, Citing Oversight Concerns Apr 22, 2026 Replimune Stock Jumps After Health Secretary Disavows Role in FDA Rejection Apr 22, 2026 Mizuho Singles Out Two U.S. Business-Services Names Poised for Growth Apr 22, 2026 Northland Sees Quantum Systems Taking Over AI Training Infrastructure Apr 22, 2026 Microsoft to fold Anthropic's Claude Mythos Preview into secure coding processes Apr 22, 2026